Ipamorelin-10mg

Ipamorelin is a synthetic peptide classified as a growth hormone secretagogue (GHS) and a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a).

• Peptide Structure: Ipamorelin is a pentapeptide composed of five amino acids with the sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂.
• It mimics the action of ghrelin, a naturally occurring hormone that stimulates growth hormone (GH) release from the anterior pituitary gland.
• Unlike other GHSs (e.g., GHRP-6 or GHRP-2), Ipamorelin has high specificity for GH release without significantly affecting cortisol, prolactin, or ACTH levels.

This selective action is particularly notable because it reduces the likelihood of undesirable hormonal fluctuations often seen with other secretagogues.

Benefits:

The physiological effects of Ipamorelin are largely attributed to its ability to increase endogenous growth hormone levels in a pulsatile and physiologically mimetic manner. Documented and proposed benefits include:

1. Stimulation of Growth Hormone Secretion:
   • Promotes natural GH release without overstimulation or suppressing the body’s feedback loop.
2. Muscle Growth and Repair:
   • Enhanced GH levels can support increased protein synthesis and muscle hypertrophy, particularly in combination with resistance training.
3. Improved Recovery and Tissue Healing:
   • GH plays a key role in cellular repair processes, potentially improving recovery time from exercise or injury.
4. Fat Metabolism:
   • GH is known to enhance lipolysis, aiding in reduction of adipose tissue, especially visceral fat.
5. Sleep and Circadian Rhythm Support:
   • Users often report improved sleep quality, possibly due to GH’s influence on deep sleep phases.
6. Minimal Impact on Other Hormones:
   • Ipamorelin’s selectivity results in low to negligible increases in cortisol or prolactin, distinguishing it from older peptides like GHRP-6.

Cycle Duration:

• Common cycles last 8 to 12 weeks, followed by a 4-week off-period to allow the body to maintain sensitivity.
• Long-term use may involve intermittent cycling or dose tapering, but such protocols should be monitored under clinical or research settings.

Stacking:

• Ipamorelin is often combined with CJC-1295 (without DAC) for synergistic GH release, as CJC-1295 stimulates GHRH receptors while Ipamorelin targets GHS-R1a receptors.